Similar articles

• Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.

  Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, Korhonen S, Erkkola R, Sipilä JI, Haavisto L, Siltala M, Tuominen J, Hakalax J, Hyöty H, Ilonen J, Veijola R, Simell T, Knip M, Simell O. Näntö-Salonen K, et al. Lancet. 2008 Nov 15;372(9651):1746-55. doi: 10.1016/S0140-6736(08)61309-4. Epub 2008 Sep 22. Lancet. 2008. PMID: 18814906 Clinical Trial.
• Prevention of type 1A diabetes: update.

  Vardi P, Koren I, Bloch K. Vardi P, et al. Isr Med Assoc J. 2004 May;6(5):301-4. Isr Med Assoc J. 2004. PMID: 15151375 Review. No abstract available.
• Intervention to delay the onset of diabetes mellitus in very young siblings of children with type 1 diabetes mellitus.

  Rapaport R, Nuzzo J, Schatz D, Maclaren N. Rapaport R, et al. J Pediatr Endocrinol Metab. 2001;14 Suppl 1:623-6. doi: 10.1515/jpem.2001.14.s1.623. J Pediatr Endocrinol Metab. 2001. PMID: 11393554 No abstract available.
• Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease.

  Simmons K, Michels AW. Simmons K, et al. Rheum Dis Clin North Am. 2014 Nov;40(4):797-811. doi: 10.1016/j.rdc.2014.07.008. Epub 2014 Sep 2. Rheum Dis Clin North Am. 2014. PMID: 25437293 Free PMC article. Review.
• Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol.

  Ziegler AG, Achenbach P, Berner R, Casteels K, Danne T, Gündert M, Hasford J, Hoffmann VS, Kordonouri O, Lange K, Elding Larsson H, Lundgren M, Snape MD, Szypowska A, Todd JA, Bonifacio E; GPPAD Study group. Ziegler AG, et al. BMJ Open. 2019 Jun 28;9(6):e028578. doi: 10.1136/bmjopen-2018-028578. BMJ Open. 2019. PMID: 31256036 Free PMC article.